Bacillus anthracis

Journal of Clinical Pathology

Volumn 56, Issue 3, 2003, Pages 182-187

  Spencer, R C ^a  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; PENICILLIN G;

ANTHRAX; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE; CLINICAL FEATURE; DISEASE ASSOCIATION; GASTROINTESTINAL SYMPTOM; LABORATORY TEST; MENINGITIS; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RISK FACTOR; SKIN MANIFESTATION; TERRORISM; VACCINATION;

ANTHRAX; ANTHRAX VACCINES; ANTI-BACTERIAL AGENTS; BACILLUS ANTHRACIS; BIOTERRORISM; HUMANS; VACCINATION; VIRULENCE;

EID: 0037341503     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.56.3.182     Document Type: Review

References (70)

1. Bush LM, Abrams BH, Beall A, et al. Index case of fatal inhalational anthrax due to bioterrorism in the United States. N Engl J Med 2001;345:1607-10.
2. Spencer RC, Wilcox MH. Agents of biological warfare. Rev Med Microbiol 1993;4:138-43.
3. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon. JAMA 1999;281:1735-45.
4. Spencer RC, Lightfoot NF. Preparedness and response to bioterrorism. J Infect 2001;43:104-10.
5. Redmond C, Pearce MJ, Manchee RJ, et al. Deadly relic of the Great War. Nature 1998;393:747-8.
6. Wheelis M. Biological sabotage in World War I. In: Geissler E, van Courtland Moon JE, eds. Biological and toxin weapons: research, development and use from the Middle Ages to 1945. Oxford: Oxford University Press, 1999:35-62.
7. Carter GB. Chemical and biological defence at Porton Down: 1916-2000. London: HMSO, 2000.
8. Carter GB. Biological warfare and biological defence in the United Kingdom: 1940-1979. Journal of the Royal United Services Institute for Defence Studies 1992;137:67-74.
9. Guillemin J. Anthrax: the investigation of a deadly outbreak. Berkley, California: University of California Press, 1999.
10. World Health Organisation. Health aspects of chemical and biological weapons. Geneva: WHO, 1970.
11. Lightfoot N, Wale M, Spencer R, et al. Appropriate responses to bioterrorist threats. BMJ 2001;323:877-8.
12. Ala'Aldeen D. Risk of deliberately induced anthrax outbreak. Lancet 2001;358:1386-8.
13. Quinn CP, Turnbull PCB. Anthrax. In: Collier L, Balows A, Sussman M, eds. Topley and Wilson's principles of bacteriology, virology and immunity, Vol. 3, 9th ed. London: Edward Arnold, 1998:799-818.
14. Dixon TC, Meselson M, Guiliemin J, et al. Anthrax. N Engl J Med 1999;341:815-26.
15. Swartz MN. Recognition and management of anthrax - an update. N Engl J Med 2001;345:1607-10.
16. Baillie L, Read TD. Bacillus anthracis: a bug with attitude. Curr Opin Microbiol 2001;4:78-81.
17. Turnbull PCB. Definitive identification of Bacillus anthracis - a review. J Appl Microbiol 1999;2:237-40.
18. Keim P, Kalif A, Schupp J, et al. Molecular evolution and diversity in Bacillus anthracis as detected by amplified fragment length polymorphism markers. J Bacteriol 1997;3:818-24.
19. Keim P, Price LB, Klevystka AM, et al. Multiple-locus variable number tandem repeat analysis reveals genetic relationships with Bacillus anthracis. J Bacteriol 2000;182:2928-36.
20. Jackson PJ, Hugh-Jones ME, Adair DM, et al. PCR analysis of tissue samples from the 1979 Sverdlovsk anthrax victims: the presence of multiple Bacillus anthracis strains in different victims. Proc Natl Acad Sci USA 1998;95:1224-9.
21. Manchee RJ, Brosler MG, Stagg AJ, et al. Formaldehyde solution effectively inactivates spores of Bacillus anthracis on the Scottish Island of Gruinard. Appl Environ Microbiol 1994;60:4167-71.
22. Carman JA, Hamblelon P, Melling J. Bacillus anthracis, in isolation and identification of micro-organisms of medical and veterinary importance. In Collins CH, Grange GM, eds. Society of Applied Bacteriology Technical Series 21. London: Academic Press, 1985:207-14.
23. Knisely RF. Selective medium for Bacillus anthracis. J Bacteriol 1966;92:784-6.
24. Hanna P. Anthrax pathogenesis and host response. Curr Top Microbiol Immunol 1998;225:13-35.
25. Little SF, Ivins BE. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect 1999;1:131-9.
26. Leppla SH. The anthrax toxin complex. In: Alouf J, Freer JH, eds. Sourcebook of bacterial protein toxins. London: Academic Press 1991:277-302.
27. Leppla SH. Anthrax toxin edema factor; a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc Natl Acad Sci U S A 1982;79:3162-6.
28. Leppla SH. Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eukaryotic cells. Adv Cyclic Nucleotide Protein Phosphonylation Res 1984;17:189-98.
29. O'Brien J, Friedlander A, Drier T, et al. Effects of anthrax toxin compounds on human neutraphils. Infect Immun 1985;47:306-10.
30. Makins S-I, Ucluda I, Terakads N, et al. Molecular characterisation and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J Bacteriol 1989;171:722-30.
31. Friedlander AM, Welkoss L, Pitt MLM, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis 1993;167:1239-43.
32. Lincoln RE, Walker JS, Klein F, et al. Value of field data for extrapolation in anthrax. Fed Proc 1967;26:1558-62.
33. Dahlgren CM, Buchanan LM, Decker HM, et al. Bacillus anthracis aerosols in goat hair processing mills. Am J Hyg 1960;72:24-31.
34. Myenye KS, Siziya S, Peterson D, Factors associated with human anthrax outbreak in the Chikupo and Nganda villages of Murewa district in Mashonaland East Province, Zimbabwe. Cent Afr J Med 1996;42:312-15.
35. Abdenour D, Larouze B, Dalichaouche M, et al. Familial occurrence of anthrax in Eastern Algeria. J Infect Dis 1987;155:1083-4.
36. Turner M. Anthrax in humans in Zimbabwe. Cent Afr J Med 1980;26:160-1.
37. Nalin DR, Sultana B, Sahunja R, et al. Survival of a patient with intestinal anthrax. Am J Med 1977;62:130-2.
38. Whitford HW. A guide to the diagnosis, treatment and prevention of anthrax. World Health Geneva: Organisation 1987.WHO/ZOON/87.163.
39. Christie AB. Anthrax. In: Infectious diseases, epidemiology and clinical practice, 4th ed. Edinburgh: Churchill Livingstone, 1987:983-1003.
40. Kobuch WE, Davis J, Fleischer K, et al. A clinical and epidemiological study of 621 patients with anthrax in Western Zimbabwe. Salisbury Med Bull 1990;68(suppl):34-8.
41. Ndyabahinduka DGK, Chu IH, Abdou AH, et al. An outbreak of human gastro-intestinal anthrax. Ann 1st Super Sanita 1984;20:205-8.
42. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7:933-44.
43. Brachman P. Inhalation anthrax. Ann N Y Acad Sci 1980;353:83-93.
44. Shafazand S, Doyle R, Ruoss S, et al. Inhalational anthrax: epidemiology, diagnosis and management. Chest 1999;116:1369-76.
45. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-8.
46. Albrink WS, Brook SM, Biron R, et al. Human inhalation anthrax: a report of three fatal cases. Am J Pathol 1960;36:457-71.
47. Plotkin SA, Brachman PS, Utall M, et al. An epidemic of inhalation anthrax, the first in the twentieth century. Am J Med 1960;29:992-1001.
48. Enticknap JB, Galbraith NS, Tomlinson AJ, et al. Pulmonary anthrax caused by contaminated sacks. Br J Ind Med 1968;25:72-4.
49. Haight TH. Anthrax meningitis: review of literature and report of two cases with autopsies. Am J Med Sci 952;224:57-69.
50. Tahernia AC, Hashemi GH. Survival in anthrax meningitis. Pediatrics 1972;50:329-33.
51. Friedlander AM. Anthrax: clinical features, pathogenesis and potential biological warfare threat. In: Remington JS, Swartz MN, eds. Current clinical topics in infectious diseases, Vol. 20. Maiden, Massachusetts: Blackwell Sciences, 2000:335-49.
52. Harrison LH, Ezzell JW, Abshire TG, et al. Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis 1989;160:706-10.
53. Update. Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy. MMWR Morb Mortal Wkly Rep 2001;50:909-19.
54. Baillie, L. The development of new vaccines against Bacillus anthracis. J Appl Microbiol 2001;91:609-13.
55. Turnbull PCB. Anthrax vaccines: past, present and future. Vaccine 1991;9:533-9.
56. Tumbull PCB. Current status of immunisation against anthrax: old vaccines may be here to stay for a while. Curr Opin Infect Dis 2000;13:113-20.
57. Shylakov EN, Rubenstein E. Human live anthrax vaccine in the former USSR. Vaccine 1994;12:727-30.
58. Dang SL. Progress in the control and research of anthrax in China. Salisbury Med Bull 1990;68(suppl):104-5.
59. Hambleton P, Carman JA, Melling J. Anthrax: the disease in relation to vaccines. Vaccine 1984;2:125-32.
60. Wright GG, Hedberg MA, Stein JB. Studies on immunity in anthrax III. Elaboration of protective antigen in a chemically defined non-protein medium. J Immunol 1954;72:263-9.
61. Anonymous: Vaccine against anthrax. BMJ 1965;ii:717-18.
62. Ivins BE, Fellows P, Pitt MLM, et al. Efficacy of standard human anthrax vaccine against Bacillus anthracis aerosol spore challenge in rhesus monkeys. Salisbury Med Bull 1996;87:125-6.
63. Ivins BE, Pitt MLM, Fellows PF, et al. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 1998;16:1141-8.
64. Bernard JP, Friedlander AM. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect Immun 1999;67:562-7.
65. Baillle L, Moir A, Manchee R. The expression of the protective antigen of Bacillus anthracis and Bacillus subtilis. J Appl Microbiol 1998;84:741-6.
66. Gupta P, Waheed SM, Bhatnagar R. Expression and purification of the recombinant protective antigen of Bacillus anthracis. Protein Expr Purif 1999;16:369-76.
67. Okinaka RT, Cloud K, Hampton O, et al. Sequence and organisation of pXO1, the large Bacillus anthracis plasmid harbouring the anthrax toxin genes. J Bacteriol 2000;181:6509-15.
68. Okinaka RT, Cloud K, Hampton O, et al. Bacillus anthracis plasmid pXO2, complete sequence 2000. Genbank Accession NC 002146, (http://www.ncbi.nlm.nih.gov/Entrex/index.html].
69. Bradley KA, Mogridge J, Mourez M, et al. Identification of the cellular receptor for anthrax toxin. Nature 2001;414:225-9.
70. Paunifer AD, Wong TY, Schwarzenbacher R, et al. Crystal structure of the anthrax lethal factor. Nature 2001;414:229-33.